• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALPN

    Alpine Immune Sciences Inc.

    Subscribe to $ALPN
    $ALPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: alpineimmunesciences.com

    Recent Analyst Ratings for Alpine Immune Sciences Inc.

    DatePrice TargetRatingAnalyst
    4/9/2024$55.00Buy
    Guggenheim
    2/15/2024$44.00Outperform
    Wolfe Research
    10/18/2023$18.00Buy
    Berenberg
    10/17/2023$18.00Buy
    Berenberg
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    6/26/2023$14.00Outperform
    Oppenheimer
    1/19/2023$17.00Overweight
    Morgan Stanley
    11/21/2022$15.00Outperform
    SVB Leerink
    See more ratings

    Alpine Immune Sciences Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Alpine Immune Sciences Inc.

      15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/30/24 9:12:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:07 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:33 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Alpine Immune Sciences Inc.

      25-NSE - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/20/24 9:37:11 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:53:25 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:52:49 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:51:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:50:57 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:50:25 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Alpine Immune Sciences Inc.

      S-8 POS - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/20/24 8:49:56 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

      FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c

      7/9/24 7:30:00 AM ET
      $ALPN
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Reports First Quarter 2024 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March

      5/9/24 4:00:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

      -- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, resolution of hematuria, and stable renal function (eGFR) -- -- Company reports successful end of phase 2 meeting with FDA, supporting advancement to a registrational, placebo-controlled phase 3 study of povetacicept in IgA nephropathy, targeted in 2H 2024 -- -- Company will host an investor call and webcast today at 5:15 pm ET -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and

      4/10/24 4:15:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

      - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com

      4/10/24 4:01:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024

      -- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with the poster presentation on April 15th -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16,

      4/1/24 9:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

      -- Povetacicept demonstrates greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion -- -- Povetacicept exhibits greater distribution to disease-related end organs compared with WT TACI-Ig -- -- A phase 2 study in SLE (DENALI) is in preparation for initiation in 2H 2024 -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024. Presentation

      3/21/24 7:45:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. Thursday, March 28th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company will host investor meetings the same day. Live webcasts of the fireside chats will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be av

      3/20/24 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

      -- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic lupus erythematosus -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023. "2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) da

      3/18/24 4:05:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days

      3/7/24 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Alpine Immune Sciences with a new price target

      Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00

      2/15/24 6:19:18 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/18/23 7:51:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/17/23 8:14:34 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Alpine Immune Sciences with a new price target

      RBC Capital Mkts initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $19.00

      10/5/23 7:23:59 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Alpine Immune Sciences with a new price target

      Oppenheimer resumed coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $14.00

      6/26/23 7:23:08 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Alpine Immune Sciences with a new price target

      Morgan Stanley initiated coverage of Alpine Immune Sciences with a rating of Overweight and set a new price target of $17.00

      1/19/23 7:17:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Alpine Immune Sciences with a new price target

      SVB Leerink initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $15.00

      11/21/22 7:28:24 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Peetz Christopher returned 1,900 shares to the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:14:39 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hernday Natasha

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:13:47 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Drappa Jorn

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:12:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Conway Robert E returned 50,000 shares to the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:11:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Topper James N

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:10:44 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Thompson Peter A.

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:09:42 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cui Xiangmin

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:08:26 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rickey James Paul returned 57,961 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:07:07 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Peng Stanford L returned 344,163 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:05:55 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gold Mitchell returned 109,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:04:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Healthcare Fund (Master), Lp bought $4,687,500 worth of shares (375,000 units at $12.50) (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      11/14/23 5:36:42 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 4:49:22 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 10:21:59 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      4/30/24 4:20:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      4/29/24 6:08:56 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      3/7/24 12:29:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      2/14/24 5:01:37 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      2/14/24 4:43:28 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      2/14/24 4:36:14 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      2/14/24 4:08:06 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13G/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      2/14/24 3:07:47 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Financials

    Live finance-specific insights

    See more
    • Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

      - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com

      4/10/24 4:01:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days

      3/7/24 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

      -- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored -- -- Based on this data Alpine will now seek to begin a pivotal phase 3 IgAN study in the second half of 2024 -- -- Company to host virtual investor call and webcast today at 4:30 pm ET with James Tumlin, M.D. and Jonathan Barratt, Ph.D., FRCP -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammator

      11/2/23 9:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

      RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2 2023 Initial data from both basket studies are anticipated by the end of 2023   Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022. "With the recent initiation of the RUBY-3 study in autoimmune glomerulonephritis and the imminent initiation of the RUBY-4 st

      3/23/23 4:05:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days

      3/15/23 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the

      11/7/22 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day

      - ALPN-303 well-tolerated in a Phase 1 healthy volunteer study with on-target effects on key biomarkers, supporting a highly competitive, potentially best in class profile - - Davoceticept (ALPN-202) demonstrates encouraging outcomes, especially in renal cell carcinoma, as monotherapy and in combination with pembrolizumab in ongoing NEON-1 and NEON-2 studies respectively - - Alpine management and leading experts to conduct webcast at 5:00 pm ET/2:00 pm PT today - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced clinical updates from tw

      9/12/22 4:05:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting

      - Alpine to hold Investor Event on Tuesday, April 12th at 6:00pm ET - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that Alpine will host a virtual investor event on April 12th, 2022 at 6:00pm ET, to coincide with the 2022 American Association for Cancer Research (AACR) Annual Meeting. During the investor event, Alpine will provide a corporate update on the development strategy for davoceticept (ALPN-202) and review the company's oral presentation at the AACR Annual Meeting ("Monotherapy dose escalation of davoceticept (ALPN-202), a

      3/30/22 8:05:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

      - Conference call and webcast today at 4:30 p.m. ET - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. "We have had a highly productive second quarter with substantial progress made across our portfolio highlighted by the initiation of Synergy, our international Phase 2 trial of ALPN-101, or acazicolcept, in lupus patients, the achievement of $45 million in development milestones as part of our AbbVie agreement, and the first presentation of clinica

      8/10/21 4:05:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market. Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a corporate update. Company management will also present at the following upcoming investor events and conferences: Bernstein CD28 Day Presentation: Monday, August 9, 12:15 p.m. ET (9:15 a.m. PT) Following the presentation, the pres

      8/4/21 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Alpine Immune Sciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, M.D., who will transition responsibilities to Dr. Dummer through the remainder of the year. "Wolfgang is a highly accomplished drug developer with deep expertise in rare disease, immunology, and immunotherapy. His experience working across all phases of clinical development through regulatory approval will be important as we continue to advance our pipeline of new therapie

      10/4/23 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi has more than 25 years of biopharmaceuticals leadership experience, including manufacturing, quality, and supply chain. She succeeds Wayne Gombotz, Ph.D., who will retire in August. "Christina is an accomplished industry leader and will be a key addition to our executive team as we prepare for a broad development plan for povetacicept. Her expertise and leadership will be important to Alpine as we contin

      8/22/23 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance
    • Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that, in connection with the previously announced appointment of Andrew S. Sandler, M.D. as Chief Medical Officer, it has granted Dr. Sandler an option to purchase 160,000 shares of common stock. The option will vest with respect to 25% of the shares underlying the option on the one-year anniversary of Dr. Sandler's employment start date, and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36-month period following the one-year anniversary of Dr.

      8/18/22 4:05:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

      - 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors. "We are very pleased to welcome Dr. Drappa to our Board of Directors. Jörn brings a tremendous depth of experience leading the successful development of immunology drugs across both small biotech and large pharmaceutical companies, and from early stage through commercialization," said Mitch

      7/19/22 8:05:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer. Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler's anticipated start date is August 17, 2022. "We are very excited and fortunate to have Andy join the Alpine team. His appointment comes at a time where we are quickly advancing our three development programs across multiple oncology and autoimmune disease indications," said Stanford Peng, M

      6/7/22 8:05:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg, M.D., M.A.S. as its Chief Medical Officer. Dr. Goldberg joins Alpine from Iovance Biotherapeutics, where she was Senior Vice President, Clinical Science. "We are very enthusiastic about the addition of Zelanna to the Alpine team, particularly as we pursue an expanding scope of clinical development activities across oncology and inflammatory disease indications," said Stanford Peng, M.D., Ph.D., President and Head of Research and Development

      6/2/21 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

      SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive

      12/11/20 8:00:00 AM ET
      $XOMA
      $PDLI
      $ALPN
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)